Any content you receive is for information purposes only. Always conduct your own research. *Sponsored
See Why Krypton Street Just Put COEPTIS, Inc. (Nasdaq: COEP) On This Morning's Watchlist—Monday, March 9, 2026
Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email.
Full Coverage is Starting Now
Take A Look At (COEP) While It's Still Early…
March 9, 2026
Early Coverage | See Why (COEP) is Already Up On Monday Morning Radar Dear Reader, What if one tiny Nasdaq company was suddenly stepping into two of the most closely watched arenas in the market at the same time? On one side, it has its hands on advanced cancer-focused cell therapy. On the other, it is moving into large-scale digital infrastructure tied to two of the most established block-chain networks in the world. That kind of shift is rare enough on its own. But when it happens through an $835M merger, it demands attention. The convergence of high-stakes immunotherapy and the rapid expansion of digital infrastructure is creating a dual-sector evolution that few saw coming. COEPTIS, Inc. (Nasdaq: COEP) is currently transitioning from a biopharmaceutical developer into a diversified company through a landmark $835M merger. This strategic shift positions the company at the intersection of life-saving cellular science and institutional-scale block-chain technology. And this is exactly why (COEP) is topping our watchlist this morning — Monday, March 9, 2026. But keep in mind, (COEP) has less than 5M shares listed as available to the public. When companies have small public floats like this, the potential exists for big moves if demand begins to shift. In just over the last month, (COEP) has made an approximate 28% move, from around $10.49 on February 5 to $13.46 on March 5, according to data available from Barchart. 
Now, (COEP) is trending near or above several key technical levels, including its 5-day, 20-day, and 50 day moving averages. With its 100-day moving average still out up above at around $14.34, we're keeping all eyes on (COEP) right now. Inside COEPTIS' Shift Toward Digital Infrastructure
Coeptis Inc. (Nasdaq: COEP), headquartered in Wexford, PA, was built around biopharmaceutical development, with programs focused on cancer, autoimmune conditions, and infectious diseases. Through subsidiaries including Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies, Inc., the company assembled a portfolio centered on cell therapy platforms and related technologies. As part of its merger with Z Squared, Coeptis has also outlined plans to separate its biopharmaceutical programs into a standalone entity while the public company shifts its focus toward digital infrastructure. At the center of that therapeutic portfolio are assets licensed from Deverra Therapeutics, including DVX201, a clinical-stage, unmodified natural killer (NK) cell therapy platform. This allogeneic approach is intended to support off-the-shelf treatment development, which could help address some of the logistical challenges associated with patient-specific therapies. (COEP) is also advancing SNAP-CAR, a universal multi-antigen CAR technology licensed from the University of Pittsburgh. The platform is being developed with the goal of targeting multiple tumor antigens at the same time, an approach researchers believe may help address antigen escape, a known challenge in treatment resistance. In addition, the company's GEAR cell therapy and companion diagnostic platforms are being developed in collaboration with VyGen-Bio and researchers at the Karolinska Institute. Alongside these therapeutic efforts, (COEP) has established a Technology Division focused on operational tools intended to improve efficiency across the organization. According to company materials, this division includes AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, aimed at streamlining internal workflows and supporting broader execution. That brings us to the transaction now redefining the company's direction. The Z Squared Integration: A Digital Powerhouse
The most significant development in the company's history is the transformational merger with Z Squared. This move effectively transitions COEP into a dual-sector entity. Z Squared is a digital infrastructure company focused on securing two of the most established decentralized networks: Dogecoin (DOGE) and Litecoin (LTC). Upon the final closing of the merger, Z Squared is expected to deploy a massive fleet of 9,800 ASIC miners across state-of-the-art facilities in North Carolina, South Carolina, and Iowa. This deployment is projected to make the combined entity the largest publicly-traded "pure-play" Dogecoin miner in the United States. The operational philosophy of Z Squared is rooted in institutional-scale discipline. Unlike speculative entities that hold digital assets for long-term appreciation, the company prioritizes immediate liquidity and stable ca-sh flow. Mined assets are typically converted to USD or stablecoins within 24 hours. This strategy is designed to provide a consistent revenue stream that can be used to fund the high-cost research and development cycles inherent in the biopharmaceutical sector. Navigating the $835M Strategic Pivot
The traditional biopharmaceutical model often involves years of high-burn research with no guaranteed revenue until a product reaches the market. By integrating a digital infrastructure division, (COEP) is pioneering a "Hybrid Model." This approach addresses the volatility of the biotech sector by tethering it to the growing demand for digital asset security. As the Litecoin and Dogecoin networks continue to gain institutional recognition, the demand for reliable, large-scale mining operations like those managed by Z Squared is expected to increase. Competitive Positioning in Cell Therapy
While the digital mining operations provide the fuel, the scientific pipeline remains the engine for long-term value. The SNAP-CAR platform's ability to target multiple antigens simultaneously places (COEP) at the forefront of the next generation of immunotherapy. Most current CAR-T therapies target a single antigen, which can lead to relapse if the cancer mutates. The "universal" nature of COEP's technology is designed to make these therapies more adaptable and durable for patients with hard-to-treat solid tumors. Operational Achievements and the $835M Valuation
In early 2026, the SEC declared the company's S-4 registration statement effective, a critical milestone that allowed for the mailing of proxies and the subsequent shareholder approval of the merger. This move was supported by detailed transaction structures valuing the deal at $835M. According to published reports, this valuation anchors the company's dual-sector strategy, providing a clear benchmark for its new market positioning. The management team, led by experienced executives in both the medical and technological fields, has successfully navigated the complexities of merging a regulated healthcare company with a high-tech infrastructure firm. This leadership is critical as the company begins to integrate the 9,800 miners into its operational reports, shifting the financial narrative from purely clinical-stage to revenue-generating. Analyzing the Financial Trajectory
The fiscal 2026 outlook for (COEP) is centered on the activation of its mining fleet. The transition from a company with an $800M+ valuation anchor to one that is actively reporting ca-sh flow from digital assets is a significant potential catalyst. The company's focus on North American infrastructure ensures that its mining operations are conducted within a stable regulatory and power-grid environment, mitigating many of the risks associated with international mining operations. Furthermore, the technology assets acquired from NexGenAI are already being utilized to optimize the company's internal data management. By applying AI to clinical trial data and marketing outreach, (COEP) is attempting to shorten the feedback loop for its therapeutic programs. This technological synergy between the biotech and digital divisions is what the company believes will lead to improved patient outcomes and superior operational efficiency. 7 Reasons Why (COEP) Is Topping Our Watchlist This Morning
—Monday, March 9, 2026…
1. Low Float: With fewer than 5M shares listed as available to the public, (COEP)'s small float could have the potential for big moves if demand begins to shift. 2. Recent Momentum: Over the past month, (COEP) moved approximately 28%, from around $10.49 on February 5 to $13.46 on March 5 according to Barchart data. 3. Technical Alignment: Currently, (COEP) is trending near or above its 5-day, 20-day, and 50-day moving averages, levels many market watchers monitor closely. 4. Key Resistance: With the 100-day moving average sitting near $14.34, (COEP) is approaching a technical area that could draw heightened attention. 5. Shareholder Approval: Shareholders have officially approved the merger with Z Squared, giving (COEP) a cleared path toward the company's planned $835M strategic combination. 6. Mining Expansion: Following the merger, (COEP) is expected to be connected to a deployment of roughly 9,800 ASIC miners supporting the Dogecoin and Litecoin networks across multiple U.S. facilities. 7. Dual Technologies: From multi-antigen CAR platforms licensed from the University of Pittsburgh to large-scale block-chain infrastructure through Z Squared, (COEP) sits at the intersection of two rapidly evolving technological fields. Take A Look At (COEP) While It's Still Early…
A lot is starting to line up for (COEP). With fewer than 5M shares available to the public, an approximate 28% move over the last month, and price action tracking near several key moving averages, this is already a name drawing increased attention. Now add in shareholder approval for the Z Squared merger, the planned $835M combination, and expected exposure to roughly 9,800 ASIC miners tied to the Dogecoin and Litecoin networks, and (COEP) becomes an especially interesting name to have on your radar. We have all eyes on (COEP) this morning—Monday, March 9, 2026. Take a look at (COEP) while it's still early. Also, keep a lookout for my next update, it could be coming before the bell rings. Sincerely, Alex Ramsay
Co-Founder / Managing Editor
Krypton Street Newsletter
| 
Tidak ada komentar:
Posting Komentar